ReViral is a biotechnology company that develops and offers antiviral therapies for patients.
ReViral has raised €37M across 1 funding round from 1 investor, most recently a Series C round in Aug 2020. Based in Stevenage, UK; founded 2011; active in Healthtech. Acquired by Pfizer in 2022. Data as of 7 Aug 2026.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-08-27 | Series C | €37M | CR-CP Life Science Fund | View deal → |
